• American Academy of Neurology warns of critical neurologist shortfall amid increased incidence of brain disorders
• Brain Scientific addresses issue with portable, cost-effective brain diagnostic solutions that record EEGs in nearly any setting
• Product development includes creation of AI and ML algorithms to detect seizures, dementia and other brain-related conditions
• NeuroCap and NeuroEEG device patents approved in U.S., Europe and China

With a goal of addressing the current acute neurologist shortfall in the United States (https://ibn.fm/DrxvC), Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, has developed cost-effective and portable proprietary medical devices that are positioned to disrupt the electroencephalogram (“EEG”) market.

According to a report from the American Academy of Neurology 2019 Transforming Leaders Program, nearly every U.S. state is experiencing a neurologist shortfall amid an increase in neurological disorders (https://ibn.fm/DrxvC). Experts warn that access to high-level care and diagnosis is immediately required to reduce mental disability, improve patient outcomes and increase the wellbeing of the current pool of neurologists facing quality of life issues.

As part of the effort to address the shortfall, Brain Scientific aims to support the industry with the introduction of cost-effective, disposable brain diagnostic solutions that include the NeuroCap(TM) and NeuroEEG(TM). These portable devices are part of the company’s expanded vision for neurology telemedicine, allowing practitioners to collect diagnostic information quickly, upload it to cloud-based infrastructure, and leverage artificial intelligence (“AI”) and machine learning (“ML”) algorithms to detect seizures, dementia and other brain-related conditions.

Brain Scientific’s go-to-market strategy emphasizes relationships with leading hospitals, in addition to prioritizing the creation of partnerships with industry leaders in EEG manufacturing and distribution. With an aim to further increase market penetration, the company endeavors to integrate its EEG solution with existing telemedicine platforms to serve the direct neurology market in addition to bundling its diagnostic solutions with products in related sectors to service complimentary markets.

The first phase of the company’s three-stage development process was completed in 2019 with the creation of the NeuroCap and NeuroEEG devices. Currently in its second development phase, Brain Scientific is now focused on the creation of secure cloud-based infrastructure to transmit data between neurologists and patients. The final phase, scheduled for late 2021 and 2022, will focus on the development of AI and ML functionality to provide predictive analytics that increases the diagnostic capabilities offered by its devices.

Brain Scientific’s NeuroCap and NeuroEEG devices can be used to record EEGs in settings of all types such as neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. With patents already approved in the United States, Europe and China, the company is positioned to dominate the market for portable brain imaging devices to address the current neurologist shortfall, improve patient outcomes and expand its vision for telemedicine in the neurology industry.

For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Flora Growth Corp. is a Colombian cannabis cultivator that is building a global cannabis CPG portfolio of premium brands and products
• Flora Growth recently announced an LOI designed to grant it an in-road to Australia’s over-the-counter medical cannabis and CBD commercial markets
• The company also signed an LOI to distribute popular Canadian pain topical brand KaLaya throughout Latin American countries, with exports planned to the United States, and to infuse its established line of products with CBD
• Market analysts predict Australia’s medial cannabis market will explode from about $150 million this year to more than a billion dollars by 2025

The Colombia-based operations of cannabis cultivator, global brand builder and product distributor Flora Growth (NASDAQ: FLGC) are receiving increased attention from market watchers, particularly in the wake of the company’s announcement that it executed a letter of intent (“LOI”) with Australia’s Evergreen Pharmacare Pty Ltd. to supply medical-grade dried flower and derivative cannabis products to Australians through Evergreen’s pharmacy distribution network.

A July 27 statement issued by Flora Growth indicated Evergreen helps patients and healthcare practitioners, primarily physicians and pharmacists, obtain medical cannabis products and provides them with additional cannabis-related education about its use, authorization and regulation. Flora Growth will begin shipping its medical-grade cannabis products as soon as it harvests its first commercial crop and secures the necessary export licenses (https://cnw.fm/YefTQ).

Market analysts at FreshLeaf Analytics (https://cnw.fm/ValZP) and Prohibition Partners (https://cnw.fm/Ob8Ab) predict the medical cannabis segment will range in value from about US$150 million this year to up to US$1.5 billion by 2025, and the LOI between Flora Growth and Evergreen positions the Colombian grower (with headquarters in Miami, Florida) at the leading edge of a burgeoning market.

“This agreement also provides significant potential upside by allowing us to work with Australian regulators directly and bring our premium brands and established product formulations to the over-the-counter CBD market,” Chief Revenue Officer Jason Warnock stated in the company’s news release, adding that Australian regulators’ recent decision to down-schedule cannabidiol (“CBD”) to a level where it can be sold as an over-the-counter product opens the door to Flora’s strategy for “providing proven cannabinoid wellness and beauty products to consumers around the world.”

Flora Growth also recently announced that it has signed an LOI to form a joint venture with Canadian-based Avaria Inc., which manufactures pain cream under its flagship brand KaLaya. KaLaya is distributed nationwide across Canada and anticipates distribution across Latin American countries under the JV, with exports to the United States as Flora Growth manages registration, sales and distribution needs. The upside here is not only bringing these well-received products to international markets, but to also infuse these products with cannabinoids, particularly CBD, in order to generate incremental revenue.

Avaria does not currently hold a license in Canada to produce cannabis derived versions of its products at a commercial scale, so the partnership would see Flora Growth’s lab division providing it with a necessary boost to expand its market reach as it supplies the cannabis derivative products and low-cost manufacturing locally in Colombia.

In Canada, KaLaya has been recognized as the most popular topical analgesic brand distributed through Canadian retailer Purity Life and by The Shopping Channel in 2020, weighing in as Canada’s fastest growing topical decongestants and analgesics brand, according to Nielsen Market Track.

“Given CBD’s association with wellness, KaLaya’s established formulation, and Flora Growth’s low-cost high-quality cannabis, this is a natural partnership we are excited to bring globally,” Flora Growth President and CEO Luis Merchan stated in the news release.

For more information, visit the company’s website at www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

If you’ve ever had to jump-start a gas-powered car, then you know it’s a pretty straightforward process: find a car that’s still running, hook a couple of jumper cables from the functioning battery to the dead one and start the other car. But for electric vehicles (“EVs”), which run on rechargeable lithium-ion battery packs rather than an internal combustion engine, the process is a little different.

While it is common knowledge that electric vehicles rely on a high-voltage battery pack for their power needs, not everyone knows that EVs also have an additional 12-volt battery similar to the one under the hood of a conventional vehicle. And just like with petrol and diesel-powered cars, your EV will be unable to start if this battery loses charge.

Save for a few safety concerns due to the nature of an EV, jump-starting your electric car is quite simple as well. For starters, never attempt to jump-start the high-voltage lithium-ion battery that provides power to your vehicle’s electric motor. Additionally, you cannot use one EV to jump-start another vehicle. In an article for Kelly Blue Book, Chris Hardesty says that an electric vehicle’s charging points are only designed to jump-start the car itself, not give another vehicle juice.

Finally, make sure the vehicle you use to jump-start the dead car has a 12-volt battery equipped with a negative grounding system, such as the ones found in gas-powered vehicles.

Now that that’s out of the way, let’s take a look at what you have to do to get your EV’s 12-volt battery going again. First, position the two vehicles so that their batteries are close together but the cars aren’t touching. Engage the parking brakes, and ensure every light and accessory in both vehicles is turned off.

Now take out your jumper cables, clamp one end of the red positive cable (+) to the dead battery’s positive terminal and the other end of the positive cable to the good battery’s positive terminal. Then clamp one end of the black negative cable (-) to the negative terminal of the good battery and the other end to the dead battery’s grounding point. Check that the clamps have solid metal-to-metal contact with the charging points and battery terminals, and ensure that the cables are away from both vehicles’ moving parts.

Once you have confirmed that the clamps have good contact and the cables are clear and won’t get snagged by moving parts, start the car with the good battery. This should be enough to jump-start your EV’s 12-volt battery, and you can now start it.

As the EV models brought to market by various sector players such as Net Element (NASDAQ: NETE) become more common, motorists will have access to a growing amount of information regarding how to maintain their electric vehicles.

NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

A mine located in Bosnia and Herzegovina may soon resume silver production, after a more than three-decade hiatus, following years of civil unrest. Paul Cronin, CEO of Adriatic Metals Plc, which is the mining company that will be handling this project dubbed the Vares project, reveals that the silver mine could begin production by next year’s end. This is part of an emerging trend that involves resuming operations in “zombie” mines that halted production due to various reasons including political unrest, owner bankruptcy or weak prices.

In an interview, Cronin, a former investment banker, stated that some of these mines, which were abandoned and are scattered across the globe, created potential environmental issues that need to be addressed. He explained that converting these unused and dumped mines into something that added value would help resolve some of these issues and allow shareholders to gain returns from them.

Over the last year, the price of silver has increased by roughly 40%, and this trend is set to continue given the metal’s use in electric vehicle charging stations and solar panels. This rise in demand for precious metals will be observed across the board. Mining companies from South Africa and Australia to Europe are being driven by the commodities price rally, which is influenced by the infrastructure spending associated with the clean energy transition and global economic recovery.

For instance, Anglo American Platinum Ltd., the largest platinum company globally in terms of market value, was recently approached by no less than three different groups regarding its Bokoni mine, which has been idle for quite some time. Cronin stated that by recycling old mines, companies could reduce their costs through the use of the existing infrastructure. This includes mines that haven’t been in production for more than three decades. He cited the example of the Vares project, which already had roads and rail links in place, noting that the company was using some of the site’s existing facilities.

Incorporating new technologies to already existing sites could also make these operations more economically viable. For example, Adriatic Metals is working to develop a zinc project in Siberia. Other mining companies getting involved with restarting operations at these mines include Mincor Resources and Panoramic Resources Ltd. Both companies are resuming production at their nickel operations after putting them on care and maintenance in 2016 following weak international prices.

In a feasibility study, Boss Energy Ltd. also revealed that its Honeymoon mine, which holds uranium and was closed in 2014 in response to weak prices, may resume operations in about 12 months.

The growing interest in zombie mines is a clear sign to mining industry players such as Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) that the foreseeable future is bright as metals prices are likely to remain steady or even rise.

NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at  https://ibn.fm/EXN

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Summary

After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. According to US marketing research firm Frost-Sullivan, AnPac Bio ranked top three globally in terms of clinical and commercial test sample numbers in the space of new cancer detection technologies in 2019. In the next five years, AnPac Bio strives to become a global leader in early cancer screening, continuing to make meaningful contributions to the global cancer prevention cause.

Lead: 

As early as 2010, AnPac Bio proposed a pan- (multiple) cancer screening theory and method to change the way science and medical professional perform cancer tests. The hope was to help cancer testing become cheaper, faster, earlier, and cover more cancer types in one test. Some of Anpac’s issued patents in the US and China dated original ideas as early as 2010s1-3, and clinical study data were collected and available as well in that same period.  By 2014, it had already publicly announced its cancer detection product capable of detecting 16 types of cancer, which was much earlier than other company in the market.

The medical industry was perhaps not ready, and many doubted if pan cancer screening could even be a possibly.  Some called AnPac Bio’s pan cancer idea and clinical data “too good to be true”.  Cancer experts had different opinions on this concept.  Some of them believed that cancer should be screened one by one, because some reasoned, after all, each cancer type is different. Some experts further believed that some cancer types are not even suited for blood tests such as brain tumors and esophageal cancer.  Contrary to accepted opinions, AnPac Bio believed in its groundbreaking idea and innovation, forged ahead and persisted in proving out its Cancer Differentiation Analysis platform.

Dr. Chris Yu, Chairman and CEO of ANPC stated, “In the past ten years, AnPac Bio has spared no effort in pioneering this concept, even though we were doubted and laughed at by some people in the field. Our hard work to validate and promote the approach includes numerous retrospective clinical trials with many hospitals (no fewer than two), prospective and follow-up studies, significant applied and published patent applications involving pan-cancer screening claims in multiple countries, various publications at technical conferences including ASCO in the US4-7, and news releases. At the same time, with the active promotion and progress of peer companies in the field, and extensive data validating this concept first by AnPac Bio (Anpac Bio published at 2015 ASCO) and later by other companies, the innovative theory of pan-cancer screening was finally accepted by most of the industry over the last few years. Although groundbreaking innovation is often lonely and hard, we must always believe in ourselves and perseverance.”

Dr. Chris Yu’s highly successful career included significant research work at three US Fortune 500 company and other publicly listed high tech companies, through cross-disciplinary and break through innovations. He has significantly changed the IP and technology landscape and made profound impact on the long term roadmap in at least two areas in which he has worked. He has been a co-founder or founding executive member of three publicly listed high tech companies (including two companies on the NASDAQ and one company on the Science and Technology Innovation Board of the Shanghai Stock Exchange). He is an inventor of over 300 patent applications in about 20 countries and regions around the world, of which nearly 200 have been granted. He has repeatedly developed cross-disciplinary innovation ideas and successfully commercialized winning products based on those ideas, with a global revenue exceeding USD $4 billion.

Dr. Yu was born in a medical family and studied at Shanghai Second Medical College (now Shanghai Jiao Tong University School of Medicine). However, he was diagnosed with partial color blindness and had to switch his major to physics. After receiving a PhD degree in physics (with a PhD thesis on a novel detection technology for weak signal detection and processing) from Pennsylvania State University, he worked at leading US semiconductor companies including Micron Technology and Motorola.  After returning to his hometown Shanghai, China, beginning in 2008, Dr. Yu began contemplating how physics, IC technologies, and his knowledge about signal detection and processing can be used for cancer detection. Dr. Yu believed that the measurement of biophysical properties could be combined with his extensive work experience in the semiconductor industry to design and fabricate novel and highly sensitive sensors. Therefore, the use of an innovative IC device with unique sensors for the detection of biophysical characteristics in blood in order to detect cancer earlier became the original development concept of AnPac Bio.

He and his co-inventor filed their first patent application in 2009, and co-founded AnPac Bio in 2010, looking to develop a cost-effective pan cancer detection technology.  Dr. Yu began to devote himself to the application of fusing the latest in semiconductor design and fabrication with the measurement of biophysical properties to detect cancer. Together with co-founder Professor Herbert Yu and R&D vice president Du Xuedong, he founded AnPac Bio to become one of the first companies to develop cancer screening by detecting biophysical properties.

In January 2020, AnPac Bio was listed on the US NASDAQ stock market. Based on 2020 full year and 2021 Q1 financial reports, AnPac Bio is now one of the fastest growing publicly traded companies in the field.

AnPac’s technology is around its proprietary “Cancer Differentiation Analysis”, or CDA test, which is based on the correlation between biophysical characteristics in the blood sample and cancer risk. This technology and emerging technologies such as CTC, ct-DNA and exosomes are called “next generation” cancer screening and detection technologies.

At the beginning of 2010s, AnPac Bio applied for pan-cancer detection patents and developed an important, novel sensor for detection. The company conducted clinical research with many medical institutions to collect a large number of clinical study samples (> 40,000 clinical samples).

In 2014, AnPac Bio announced that its technology is capable of detecting 16 types of cancer.  By 2015, the Company had published four papers at 2015 ASCO4-7, which included clinical study data on lung cancer, liver cancer, esophageal cancer, and colorectal cancer.

Other companies in the cancer screening space, including Grail8, and Thrive9, which is based on CancerSEEK technology originating at Johns Hopkins University, have also begun to establish pan-cancer tests.

The complete process of AnPac’s cancer detection technology involves using internally developed and fully automated equipment to detect the biophysical parameters in the blood, and then calculate data based on proprietary algorithms to assess the level of cancer risk.

The purpose of early cancer screening is for early detection, early diagnosis, and early treatment. Very often, at early cancer stage, there are no obvious symptoms, and the significance of early screening is to conduct a risk assessment when the subject has no obvious symptoms. Those who are assessed as having a high risk of cancer is advised to go to a medical institution for further examination, so that they can discover potential cancer earlier.

AnPac Bio detects the biophysical parameters in the blood. This technology has the advantages of detecting multiple cancer types at early stage, with a high sensitivity and specificity, and at a lower cost.

Presently, AnPac Bio’s CDA platform can test up to 24 types of cancer in men and 26 types of cancer in women at one time, and the types of cancers detected are increasing. In addition to screening cancer patients, based on the follow-up data of more than 14,000 subjects, AnPac Bio’s detection technology has also detected a large number of patients with precancerous lesions. “This shows that our technology can also identify pre-cancer diseases and risk.” Dr. Yu stated.

“Before, there are many cancer types that cannot be easily detected and screened, and they have no known- bio-markers, however, our CDA technology can be used for preliminary screening. We fill the technological gap in this area. For example, with esophageal cancer and brain tumor, there are currently no established bio-markers available. The traditional method of esophageal cancer detection is endoscopy, but AnPac Bio’s technology can use blood to screen for esophageal cancer.” Dr. Yu continued.

Since its founding, AnPac Bio has firmly established the direction of independent research and development for the application of biophysics in high-throughput pan-cancer screening. The use of proprietary equipment has resulted in huge advantages in operating costs and company growth. In 2020, under a global health pandemic, cancer screening industry was greatly affected. However, revenue of AnPac Bio increased by 89% year-over-year, and its loss decreased by 20% year-over-year, which put AnPac Bio at one of the best performing companies (in terms of revenue growth and net loss decrease) in the field.  This significant advantage is expected to continue.

The higher rate of revenue growth over its publicly traded peers by AnPac Bio indicates that its technology and products are gaining increased market acceptance and market share.

Early cancer screening is an area that requires long-term investment. At present, the early cancer screening industry still faces many challenges. In addition to the need to continuously improve detection sensitivity and specificity, the difficulties include reducing detection costs and enhance market acceptance. AnPac Bio is well prepared to meet the above stated challenges, with its low cost structure, pan cancer screening strategy, and improving cancer detection sensitivity and specificity with further optimized algorithm (with increased larger data set) and new generation of sensors.

AnPac Bio recently announced completion of research and development, and validation of a new generation of sensors. “The design and process flow of the chip has been further optimized, which resulted in sensor device yield increase, and significant improvement in detection signal stability.” Dr. Yu said.

Normally, if a subject is assessed to be at high risk after an early cancer screening through a CDA test, the next step may be further testing and diagnosis in the hospital, and then cancer treatment. Cancer treatment is of course a crucial area in the medical field. For AnPac Bio, it may also be an extension of the company’s core technology which includes its expertise in biophysics and IC design and fabrication, as well as its deep understanding on what and how biophysical properties may have played a role in cancer evolution, and how biophysical signals change as the disease evolution is taking place.

“We have collected a significant amount of clinical data and found that as the condition of the potential cancer patients develops, biophysical indicators also change in a statistically significant way. We believe that the changes in biophysical indicators are related to the progression of the disease,” said Dr. Yu.

“Research by other groups have also found that changes in the micro-environment may lead to increased genetic mutations and cell division errors, which may further lead to diseases, including cancer. We are trying to explore whether we can use biophysical intervention and treatment methods to control diseases and prevent it from progression, or even directly reverse the process. Physical or Biophysical treatment technologies have already been successfully applied in certain cancer therapeutic fields, and AnPac Bio is also confident in attempting to develop our own novel technology in this area.”

The Company has continued to make progress towards its goals in 2021. On January 25, China’s National Medical Products Administration (NMPA) approved AnPac Bio to start the registration and testing of its Class III lung cancer auxiliary diagnostic medical devices in its designated medical device testing laboratory.

In late May, AnPac Bio announced that it would develop innovative cancer treatment technologies based on a biophysical approach. It is expected that the new technology will use key therapeutic modules manufactured by IC technology to intervene and treat cancer patients who exhibit abnormal biophysical characteristics. This project is expected to begin laboratory tests in the third quarter of 2021.

AnPac Bio continues to make tangible contributions to the cause of cancer prevention via its efforts in groundbreaking novel ideas, and develop them into cost effective products and services to benefit society as a whole. “We hope that in the future, AnPac Bio will become a role model of science and technology, as well as innovation.” Dr Yu stated.

References

(1)      US Patent# 9,408,565.

(2)      US Patent# 9,689,863.

(3)      Chinese Patent# CN 103608682 B.

(4)      Y. Zhang, et al., Abstract# e12578, J Clin Oncol 33, 2015.

(5)      J. Ji, et al., Abstract# e22171, J Clin Oncol 33, 2015.

(6)      X. Du, et al., Abstract# e12587, J Clin Oncol 33, 2015.

(7)      G. X. Jiang, et al., Abstract# e15059, J Clin Oncol 33, 2015.

(8)      GRAIL Press Release https://grail.com/press-releases/grail-announces-positive-new-data-with-multi-cancer-early-detection-blood-test-from-ccga-study/

(9)      J.D. Cohen, et al., Science 10.1126/science.aar3247(2018)

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Third-Party Content

The BMW website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the BMW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of BMW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and BMW does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by BMW providing you with this internet portal that makes accessible to you the ability to view third party content through the BMW site, BMW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. BMW expressly disclaims liability relating to such third-party content. BMW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, BMW reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.biomedwire.com/disclaimer.

• AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
• The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
• CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
• The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
• The global cancer diagnostics market is expected to reach $249.6 billion by 2026

AnPac Bio-Medical Science Co. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance.

AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is situated in Philadelphia, Pennsylvania. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States.

Cancer Differentiation Analysis (“CDA”)

Cancer Differentiation Analysis (“CDA”) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form.

Most liquid-based cancer screening and detection technologies focus on biochemical signals, like conventional biomarkers and genomic signals, such as ct-DNAs and CTCs (circulating tumor cells in the blood). These typically only determine whether or not cancer has occurred at a fixed point in time.

CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future – all through a standard blood test, at a competitive price point.

AnPac Bio-Medical’s CDA is powered by a database of over 200,000 samples and cases and serves as a new way to approach disease and cancer screening. The device uses an integrated system of sensors to detect several biophysical signals at the cellular, protein and molecular levels. CDA leverages a proprietary algorithm to synthesize the data, effectively generating a personalized risk assessment for evaluated patients.

Through CDA technology, AnPac Bio-Medical aims to address a number of goals, including:

• Innovate – AnPac Bio-Medical is an innovator in the cancer screening industry, with CDA research ongoing since 2008, and commercial operations beginning in 2015. AnPac considers itself a thought leader in developing multi-cancer screening.
• Detect – AnPac Bio-Medical detects early signals of threatening cancer and its location within the body.
• Identify – CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity rates.
• Provide – The company’s platform provides multi-level, multi-parameter analysis using proprietary diagnostic algorithms, which results in accurate and easy-to-understand results.
• Proven – A fully operational analysis of over 200,000 test samples has been run to date. CDA technology has been shown to identify pre- and early-stage cancers in patients previously diagnosed as “cancer-free” through traditional methods.
• Biophysical Properties – CDA analyzes biophysical properties in human blood and the correlation between biophysical properties and cancer occurrence.

Market Outlook

AnPac Bio-Medical is exploring detection of other types of cancers leveraging its innovative CDA technology and multi-cancer screening and detection tests, which could open significant opportunities on the global cancer diagnostics market.

According to a report by Grand View Research, the cancer diagnostics market is expected to reach $249.6 billion worldwide by 2026 (https://ibn.fm/EMdoS). The market is expected to grow at a CAGR of 7% during the forecast period.

Management Team

Dr. Chris Yu is the Co-Founder and Chief Executive Officer of AnPac Bio-Medical. He has enjoyed a successful career as an innovator in life sciences, technology and engineering. Dr. Yu has worked for three U.S. Fortune 500 companies and is the first/principal inventor of over 300 patent applications spanning semiconductors, materials and life science. He has a proven history of developing cutting-edge products with long-term profit and sustainability. Dr. Yu was born to a medical doctor’s family and went to medical school. He later switched his major to physics and received his bachelor’s and master’s degrees in physics from the University of Missouri-Kansas City Campus and a doctoral degree in physics from Pennsylvania State University. Both of his dissertations addressed innovative detection techniques.

Dr. Herbert Yu is the Co-Founder and Chief Medical Officer of AnPac Bio-Medical. He is a renowned expert in molecular epidemiology, with training in medicine and chemical biochemistry. Dr. Yu has a 20-year career in leading-edge cancer research, including breakthrough work in areas of carcinogenic factors. He is a professor and research director at the University of Hawaii and an adjunct professor at Yale University. He received his bachelor’s degree in medicine from Shanghai First Medical College. Dr. Yu also received a science degree in epidemiology and a Ph.D. in clinical biochemistry from the University of Toronto.

Jingiu (Edward) Tang is the company’s Chief Financial Officer. He previously served as a global internal auditor at Natuzzi S.p.A. Mr. Tang also worked at Beijing Dongshen CPA and Shanghai De’an CPA, providing external audits, finance and tax advisory services across different industries and sectors. He is a Certified Public Accountant in Australia. Mr. Tang received his bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Weidong Dai is the company’s China General Manager. He previously served as a general partner at Stirrfir Investment Management Co. Mr. Dai has also served as the chairman of RTS Management (Shanghai) Co., and as managing director of Hong Kong Pro-Health Technology Co. and Shanghai Pro-Health Medical Devices Co. He has published a number of medical research papers and research articles in professional journals. Mr. Dai was awarded the Hong Kong Industrial Award for a medical device that he led in research and development. He earned his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from the Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

For more information, visit the company’s website at www.AnPacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Senator Cory Booker has revealed that he and his Senate colleagues are in talks with the White House regarding cannabis legalization. Now that Senate Majority Leader Chuck Schumer, Senate Finance Committee Chairman Ron Wyden and Booker have released a discussion draft of a federal marijuana legalization bill, they are working to bring President Joe Biden on board. President Biden has said that while he supports modest cannabis reform, including medical marijuana and expunging low-level cannabis offenses from people records, he opposes broad reform.

The trio released the 163-page federal cannabis bill last month, asking the public for input so they could improve it before formally introducing it for legislation. Dubbed the Cannabis Administration and Opportunity ACT (“CAOA”), the legislation would deschedule cannabis at the federal level, expunge prior marijuana-related convictions and allow states to continue maintaining their own cannabis policies, among other things. When asked how he planned on soliciting Biden’s and Vice President Kamala Harris’s support during a Q&A session on Twitter, Booker said they will start conversations with the White House now that a discussion draft of their bill is out.

While cannabis reform advocates have praised the senators’ efforts to federally legalize cannabis, there is a chance Biden might veto the bill should Congress send it to his desk. Gaining his support, as hard as that may be given the president’s past as a “leading warrior in the drug war,” it increases the legislation’s odds of becoming law. However, the federal cannabis bill may not even reach the president’s desk, given how tenuous the Democrats’ hold on the Senate is.

The three Senators will have to drum up 60 votes in the Senate for the bill to pass, which seems unlikely at the momennt. Even with the Democrats’ slim majority over the GOP, some members of the party have raised concerns about the comprehensive federal cannabis bill. Some industry stakeholders believe that the Secure and Fair Enforcement (“SAFE”) Banking Act is much more likely to advance in the Senate because it has bipartisan support; however, Booker has ruled out moving it, stating that Congress first has to provide restorative justice for communities that were disproportionately affected by the drug war.

Additionally, he says that since the CAOA would federally deschedule cannabis, it would inadvertently resolve the banking issue. It would also offer a 50% tax reduction through a tax credit to small cannabis operators with less than $20 million in sales, he says.

The federal reclassification of cannabis is likely to boost the market for CBD products made by companies such as The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) since the controversy surrounding the plant may reduce and expose it to new markets and demographics.

NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The Global Market of Microreactors report centers on the potential of microreactors and the future international microreactor market, evaluating their potential deployment and unique capabilities in certain international markets in the period between 2030 and 2050. The report observes that the coming years will see a growing demand for nuclear microreactors in key markets around the world.

The study utilized various techniques to analyze rising market trends and rank markets in more than 60 nations, including newcomer countries and current users of nuclear energy in order to obtain various potential demands.

Microreactors are sometimes called nuclear batteries and are a subgroup of modular reactors with a capacity that ranges between 1 to 20 MWe. They include heat pipe reactors, molten salt reactors and light-water reactors.

The study included research conducted between 2019 and 2021, which focused on the possible applications for microreactors in the United States, Alaska and Puerto Rico’s federal facilities. These studies also included research conducted by Nuclear Alternative Project, a Puerto-Rican-led nonprofit organization that looked into the viability of the use of microreactors and small modular reactors in the provision of power to island territories such as Puerto Rico.

Research by scientists from the University of Wisconsin-Madison that defined the possible role of microreactors at government installations was also included, as well as research by the University of Alaska Anchorage that identified the economic development potential, applications and markets for nuclear-powered microreactors in the Arctic and Alaska plus its export potential for remote locations across the globe.

The report notes that the preliminary deployment of microreactors could help expand nuclear energy’s contribution in Western Europe and North America by the year 2030, adding that these areas would otherwise demonstrate minimal future growth with regard to nuclear energy. Deployments in the mid-term, which would begin by 2035, would see an expansion in Asia and Eastern Europe. Energy infrastructures are currently being developed in these regions.

In the long term, deployment in the period between 2040 and 2050 would be in big cities and urban markets that are vulnerable to climate change and lack access to energy. The report adds that to capture new market shares for microreactors, a balance between public acceptance, costs, technology performance and market demands must be achieved and some challenges defeated.

The report also notes that microreactors will not be in competition with centralized energy sources, even after they achieve deep penetration in key markets. Finally, the report highlights that some questions about microreactors, such as their transportation and fuel, as well as their physical and cyber risks, will have to be answered. Technical exchanges and collaborations, which include efforts by U.S. federal programs and efforts by Canadian and U.S. regulators, are focused on these priorities.

This bullish outlook for nuclear microreactors bodes well for uranium mining companies such as Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) since these companies will have a much bigger market to serve in the coming decades.

NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

NetworkNewsWire Editorial Coverage: One of the most pervasive diseases in first-world countries, heart disease is the leading cause of death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (“CDC”), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don’t even know they have it. The urgency of finding effective treatments for this life-threatening disease can’t be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).

• High blood pressure is a life-threatening disease that can be managed with effective treatment.
• Lexaria is a first mover in developing potential treatment base on its DehydraTECH technology.
• The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.
• Recent human clinical study using DehydraTECH technology demonstrated rapid, sustained drop in blood pressure along with excellent tolerability.

Hypertension Running Wild

Controlling blood pressure is essential to health. High blood pressure is a primary or contributing cause of death in almost 500,000 deaths a year, and hypertension can double the risk of a heart attack and quadruple the chance of having a stroke, plus raise the likelihood of heart failure, vision loss, renal disease, dementia, peripheral artery disease and more. And it’s not just an “old-person” problem; nearly one in four adults aged 20 to 44 have high blood pressure. In addition, high blood pressure costs the United States about $131 billion each year.

The good news? The disease can be managed — and even cured —  with effective treatment. With that in mind, it’s no surprise that the global anti-hypertensive drugs market is expected to grow from $24.17 billion in 2020 to $27.81 billion in 2025. Even with current hypertension drugs available, only 24% of the 108 million people in the U.S. with high blood pressure have their condition under control. It’s a market ripe for innovation.

Increasing Onset, Bioavailability, Potency

Lexaria Bioscience Corp. (NASDAQ: LEXX) may be on the forefront of some of the exciting innovation in the space. The Kelowna, British Columbia-based company has developed and patented its DehydraTECH technology, a drug-delivery platform for increasing the speed of onset, bioavailability and drug potency. The mechanics involve combining an active pharmaceutical ingredient (“API”) with fatty acid oil and then applying the mix to carrier particles, which can even be common ingredients such as tapioca starch or gum arabic. Next, a patented dehydration synthesis procedure is performed, and the product is rendered as powder or liquid for use in the desired final form factor, such as a pill, tablet, chewable or oil.

Lexaria has been working with National Research Council of Canada, the biggest R&D organization in the country, since 2017 on defining the qualities of DehydraTECH. Among other things, Nuclear Magnetic Resonance molecular characterization suggests DehydraTECH does not change the chemical structure of an API it delivers, which is critical in reliance on original API safety data in developing novel delivery methods without starting from scratch regarding the FDA process. This keeps the door open to a faster path to market.

Ultimately what this means is DehydraTECH could make lower doses of some substances more effective while even reducing side effects. The company has focused its ongoing R&D into three key segments, including pharmaceuticals and the treatment of heart disease.

Early Results Show Extreme Promise

Just last month, Lexaria announced that a human clinical study using DehydraTECH technology demonstrated a rapid and sustained drop in blood pressure along with excellent tolerability. “We are very encouraged by these early results in our 2021 hypertension program,” said Lexaria CEO Chris Bunka. “Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in stage 2 hypertensive volunteers.”

Initial results show that blood pressure was reduced across both male and female volunteers and was most pronounced in the first 10–50 minutes of the study treatment, reinforcing pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic controls. Dr. Phil Ainslie, the lead investigator on the study, commented that “these early results are extremely promising in this at-risk hypertensive population and provide a fundamental support for expansion into more prolonged repeat dosing and future longer term clinical trials.

Platform Diversification

Lexaria’s vision and focus is on several core business segments for DehydraTECH, including heart disease and hypertension, reduced-risk noncombusted nicotine and improved antiviral drug delivery, to name a few. Multiple successes on different fronts have been reported recently, including work in the antiviral program where DehydraTECH has been used to process compounds from leading drugs used for antiviral drugs for SARS-CoV-2/COVID-19 and HIV/AIDS. This is critical work not only for hopefully treating COVID-19 today but also in order to be better prepared when the next pandemic inevitably comes (think bird flu, swine flu, MERS, SARS, etc.).

The scalability to address a diverse group of market opportunities lends color to the potential of DehydraTECH. Consider the antivirals market that is in the spotlight right now because of the COVID-19 pandemic and the circulating delta variant is estimated at $52.1 billion and forecast to reach $66.7 billion by 2025. But DehydraTECH is so versatile, there are many other potential applications. Lexaria sees opportunities in human hormones (e.g., testosterone and estrogen replacement, a $21.9 billion market); oral mucosal nicotine (global smokeless tobacco products market valued at $13.6 billion in 2018), vitamin D3 ($1.1 billion market); PDE5 inhibitors ($4.4 billion market in 2014); and non-steroidal anti-inflammatories ($15.6 billion market in 2019).

Cardiovascular Disease Market Only Getting Bigger

Lexaria is only tapping into a slice of the $92.4 billion cardiovascular drug market that generates billions of dollars in profits every year for drug makers. Majors dominate this lucrative market expected to rise to $107.77 billion in 2025, fueled by a return to normal healthcare practices in a post-pandemic economy.

Pfizer Inc. (NYSE: PFE), one of the largest pharmaceutical companies in the world, notes that despite advances in care and treatment, cardiovascular disease (“CVD”) remains the number-one cause of death worldwide, with the prevalence only expected to increase. Pfizer is committed to harnessing its legacy and expertise as it aims to address gaps in CVD treatment through the development of new medicines that can meaningfully reduce CV risk for patients. Originally manufactured by Pfizer, NORVASC(R) has been available for more than 25 years and is prescribed to treat  high blood pressure (hypertension), certain types of chest pain (angina), and blocked arteries of the heart (coronary artery disease).

Merck & Company Inc. (NYSE: MRK) announced earlier this year that the FDA had granted approval to its (and Germany-based partner Bayer’s) heart-failure drug, Verquvo (vericiguat). The company noted that patients with symptomatic chronic heart failure and reduced ejection fraction have a high risk for hospitalization after experiencing symptoms of heart failure requiring outpatient IV diuretic treatment or hospitalization. Many of those, perhaps even more than half, are hospitalized within a month of discharge due to a worsening event, and approximately one in five dice within two years. The approval of VERQUVO provides doctors, health-care professionals, and patients with a new option to current available therapies.

Novartis AG (NYSE: NVS), like most other majors, is highly diversified, with its top-20 products generating $16 billion in sales during the first half of 2021. Entresto, its drug to reduce the risk of cardiovascular death and hospitalization for heart failure in certain patients, was its biggest gainer during Q2, with sales surging 53% from the year prior quarter to $886 million during the quarter. Novartis is committed to reimagining medicine and using innovative science and technology to address some of society’s most challenging healthcare issues.

AstraZeneca PLC (NASDAQ: AZN) announced in April that its proprietary sodium-glucose cotransporter 2 (SGLT2) inhibitor, Farxiga, has been approved for use in the United States. In phase 3 trials, the drug demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death. Chronic kidney disease is often associated with a heightened risk of heart disease or stroke, and the company called the approval of Farxiga, one of the most significant advancements in the treatment  of chronic kidney disease in more than 20 years.

Heart disease is the most indiscriminate killer in the United States. Every year it is a leading cause of death for men, women and people of most racial and ethnic groups. About one in every four deaths is caused by heart disease, equating to roughly 655,000 Americans each year. It’s clear that drug sales are booming trying to combat it, but any innovation to make these medicines (many of which have ugly side effects) better will almost certainly be welcomed with open arms.

For more information about Lexaria Bioscience Corp., please visit Lexaria Bioscience Corp.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

• InMed has a world class leadership team with a successful track record of drug development and commercialization
• The company recently announced closing of a $12 million private placement
• InMed has a solid and expanding intellectual property portfolio with multiple patents filed
• The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica
• InMed retains all commercial rights to its IntegraSyn manufacturing system
• InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa
• The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029

InMed Pharmaceuticals (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (“CBN”) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (“API”) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.